A perspective on the current strategies for the treatment of obesity.

Steven V Joyal
{"title":"A perspective on the current strategies for the treatment of obesity.","authors":"Steven V Joyal","doi":"10.2174/1568007043336978","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence in obesity has increased dramatically over the past 30 years, more than double in the United States alone. Obesity is associated with an increased risk for type 2 diabetes mellitus, dyslipidemia, hypertension, biliary disease, obstructive sleep apnea, and certain types of cancer. The pathophysiology of obesity is complex, involving behavioral, environmental, and genetic factors. Current treatment options include behavior modification and lifestyle changes which incorporate weight-reducing diets and physical activity, FDA approved long-term anti-obesity pharmacological agents sibutramine and orlistat, non-FDA approved over-the-counter (OTC) supplements and nutriceuticals, and, when appropriate, bariatric surgery. Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system. This brief review explores the current data available on treatments for the obese patient including the relative merits of different types of macronutrient composition (e.g., low carbohydrate vs. high carbohydrate diets) of weight-reducing diets, the value of resistance/ strength training in physical activity programs designed for the obese patient, the safety and efficacy associated with OTC supplements and nutriceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ hydroxycitric acid (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine and orlistat, and bariatric surgery.</p>","PeriodicalId":11063,"journal":{"name":"Current drug targets. CNS and neurological disorders","volume":"3 5","pages":"341-56"},"PeriodicalIF":0.0000,"publicationDate":"2004-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets. CNS and neurological disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1568007043336978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 35

Abstract

The prevalence in obesity has increased dramatically over the past 30 years, more than double in the United States alone. Obesity is associated with an increased risk for type 2 diabetes mellitus, dyslipidemia, hypertension, biliary disease, obstructive sleep apnea, and certain types of cancer. The pathophysiology of obesity is complex, involving behavioral, environmental, and genetic factors. Current treatment options include behavior modification and lifestyle changes which incorporate weight-reducing diets and physical activity, FDA approved long-term anti-obesity pharmacological agents sibutramine and orlistat, non-FDA approved over-the-counter (OTC) supplements and nutriceuticals, and, when appropriate, bariatric surgery. Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system. This brief review explores the current data available on treatments for the obese patient including the relative merits of different types of macronutrient composition (e.g., low carbohydrate vs. high carbohydrate diets) of weight-reducing diets, the value of resistance/ strength training in physical activity programs designed for the obese patient, the safety and efficacy associated with OTC supplements and nutriceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ hydroxycitric acid (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine and orlistat, and bariatric surgery.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肥胖症治疗的当前策略展望。
在过去的30年里,肥胖的流行率急剧上升,仅在美国就增加了一倍多。肥胖与2型糖尿病、血脂异常、高血压、胆道疾病、阻塞性睡眠呼吸暂停和某些类型癌症的风险增加有关。肥胖的病理生理是复杂的,涉及行为、环境和遗传因素。目前的治疗选择包括行为矫正和生活方式的改变,包括减肥饮食和体育活动,FDA批准的长期抗肥胖药物西布曲明和奥利司他,非FDA批准的非处方(OTC)补充剂和营养品,以及适当的减肥手术。政府机构表示,如果不充分预防和治疗肥胖,与肥胖相关的直接和间接成本可能会使医疗保健系统不堪重负。这篇简短的综述探讨了目前关于肥胖患者治疗的数据,包括减肥饮食中不同类型的大量营养素组成(如低碳水化合物与高碳水化合物饮食)的相对优点,为肥胖患者设计的体育活动计划中的阻力/力量训练的价值,与非处方补充剂和减肥营养品(如麻黄、共轭亚油酸(CLA))相关的安全性和有效性。藤黄果/羟基柠檬酸(HCA),铬,丙酮酸),fda批准的长期肥胖治疗西布曲明和奥利司他的安全性和有效性,以及减肥手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cannabinoids. The endocannabinoid system in the brain: from biology to therapy. Endocannabinoid metabolic pathways and enzymes. Molecular biology of the enzymes that degrade endocannabinoids. Endocannabinoids in the central nervous system: from neuronal networks to behavior.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1